Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molecular Endotypes of Chronic Idiopathic Urticaria
NCT04774315Phase 4Active, not recruiting
- Sponsor
- University of Colorado Denver
- Start
- Jan 2022
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of omalizumab in chronic idiopathic urticaria (CIU), sponsored by University of Colorado Denver. Started Jan 2022; status: active, not recruiting.
02
Drugs
omalizumab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on NCT04774315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04774315.